Department of Anatomical Pathology, Mater Health Services, South Brisbane, Queensland, Australia.
Pathology. 2013 Jan;45(1):49-54. doi: 10.1097/PAT.0b013e32835bd561.
To examine AGR2 expression in ovarian epithelial tumours and its potential role as a prognostic biomarker.
Tissue microarray technology and immunohistochemistry were used to investigate AGR2 expression in ovarian epithelial tumours and in non-neoplastic ovarian epithelium. For the carcinomas, the expression data were correlated with clinicopathological features and disease outcome.
AGR2 was expressed in all benign, borderline and malignant mucinous tumours and in a high proportion of endometrioid carcinomas (89%). AGR2 was frequently expressed in benign and borderline serous tumours (76% and 95%, respectively), but less commonly expressed in serous carcinomas (19%, p < 0.001). AGR2 expression in ovarian carcinomas was inversely correlated with p53 and p16 expression (p = 0.002 and p < 0.001, respectively), and independent of CA125 expression. AGR2 expression was more common in carcinomas which presented with early-stage compared with late-stage disease (p = 0.009) and AGR2 was expressed in carcinomas with better outcome (22% relapse rate of AGR2 positive cancers compared with 74% relapse rate for AGR2 negative cancers, p = 0.001).
Our findings indicate that AGR2 expression is associated with mucinous carcinomas and their precursor lesions and endometrioid cancers. Additionally, AGR2 may be an important prognostic biomarker of ovarian cancer.
检测卵巢上皮性肿瘤中 AGR2 的表达及其作为预后生物标志物的潜在作用。
采用组织微阵列技术和免疫组织化学方法检测卵巢上皮性肿瘤和非肿瘤性卵巢上皮中 AGR2 的表达。对癌组织，将表达数据与临床病理特征和疾病结局相关联。
AGR2 在所有良性、交界性和恶性黏液性肿瘤以及相当比例的子宫内膜样癌（89%）中表达。AGR2 在良性和交界性浆液性肿瘤中频繁表达（分别为 76%和 95%），但在浆液性癌中表达较少（19%，p<0.001）。卵巢癌中 AGR2 的表达与 p53 和 p16 的表达呈负相关（p=0.002 和 p<0.001），与 CA125 的表达无关。与晚期疾病相比，早期疾病的卵巢癌中 AGR2 的表达更为常见（p=0.009），并且 AGR2 在预后较好的癌中表达（AGR2 阳性癌症的复发率为 22%，而 AGR2 阴性癌症的复发率为 74%，p=0.001）。
我们的研究结果表明，AGR2 的表达与黏液性癌及其前体病变和子宫内膜样癌相关。此外，AGR2 可能是卵巢癌的一个重要预后生物标志物。
